Frankfurt - Delayed Quote EUR
Viking Therapeutics, Inc. (1VT.F)
As of 9:21 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Cash Flow
-71,945.00
-73,376.00
-48,397.00
-47,586.00
-21,777.00
--
Investing Cash Flow
-562,652.00
-179,086.00
54,753.00
37,960.00
41,567.00
--
Financing Cash Flow
609,056.00
271,376.00
4,163.00
6,880.00
950.00
--
End Cash Position
43,978.00
55,516.00
36,632.00
26,371.00
29,117.00
--
Repurchase of Capital Stock
--
--
-6,795.00
--
--
--
Free Cash Flow
-71,945.00
-73,376.00
-48,397.00
-47,586.00
-21,777.00
--
12/31/2019 - 5/11/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
430.F Terns Pharmaceuticals Inc
6.55
-1.50%
20D0.F Cidara Therapeutics, Inc.
10.20
0.00%
J7Z.F Jazz Pharmaceuticals plc
103.50
-0.72%
HTD.MU Corcept Therapeutics Inc
45.34
0.00%
RGO.HA Regeneron Pharmaceuticals Inc
892.20
-0.51%
BO1.MU BioCryst Pharmaceuticals Inc
6.85
-1.27%
LSRM.MU CEL-SCI Corp
0.8690
0.00%
LSRM.BE CEL-SCI Corp
0.8100
+0.06%
0RK.F Exscientia plc
4.6000
-2.13%
ISI.SG Ionis Pharmaceuticals Inc
35.72
-0.25%